NCT06960629View on ClinicalTrials.gov

The Effect of ROCK Inhibitors on Corneas of Patients With Glaucoma and Pseudophakic Bullous Keratopathy (PBK)

Enrolling by invitationOBSERVATIONAL
Enrollment

50

Participants

Timeline

Start Date

April 1, 2025

Primary Completion Date

April 1, 2026

Study Completion Date

October 1, 2026

Conditions
Pseudophakic Bullous KeratopathyGlaucoma
Interventions
DRUG

Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution

Patients with pseudophakic bullous keratopthy and glaucoma will receive topical netarsudil/latanoprost 1x daily for 3 months.

DRUG

Placebo

Patients with pseudophakic bullous keratopathy and glaucoma will receive topical placebo 8artificial tear substitute) 1x daily for 3 months.

Trial Locations (1)

10000

University Hospital Dubrava, Zagreb

All Listed Sponsors
lead

University Hospital Dubrava

OTHER